Clinical Trials Browser

Interventional × Adenoma, Islet Cell × Everolimus × Clear all

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06472388 2024-06-25

EVENET

Phase 2 Recruiting

100 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

NCT02294006 2021-09-09

MetNET1

Phase 2 Unknown

26 enrolled

Adenoma, Islet Cell

NCT00576680 2020-07-09

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Phase 1/2 Completed

43 enrolled 8 charts

Adenoma, Islet Cell

NCT01374451 2016-12-20

COOPERATE-2

Phase 2 Terminated

160 enrolled 17 charts

EndocrineNET

Adenoma, Islet Cell, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1 Completed

22 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00942682 2014-04-29

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Phase 1 Completed

21 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

Clinical Trials

STELLAR-311

ACTION-1

EVENET

MetNET1

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

COOPERATE-2

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors